Oncology
Multiple Myeloma (MM)
2
Pipeline Programs↗
4
Active Trials↗
2
Companies Involved↗
Multiple Myeloma (MM) is an early-stage landscape with 2 programs across 2 companies. The most active players are Keymed Biosciences Co.Ltd, BeOne Medicines.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 21
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
4
clinical trials
Not yet recruiting3 · 75%
Recruiting1 · 25%
Clinical Trials
Trial Activity
A Phase Ib/II, Non-Randomized, Biomarker-Stratified Umbrella Study of Chemotherapy-Free Strategies in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Status: Sonrotoclax and a BCMA/CD3 Bispecific Antibody (AL-005)
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07687004·50 enrolled
Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT07684274·290 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)